Skip to main content

Viemed Healthcare Announces Third Quarter 2025 Earnings Conference Call Details

LAFAYETTE, LA / ACCESS Newswire / October 21, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ: VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025, at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

(877) 407-6176 (US Toll-Free)

+1 (201) 689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC

Following the live call, a replay will be available in the Investor Relations section of the Company's website at https://www.viemed.com.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at https://www.viemed.com.

For further information, please contact:

Investor Relations
ir@viemed.com

Trae Fitzgerald
Chief Financial Officer
Viemed Healthcare, Inc.
(337) 504-3802

SOURCE: Viemed Healthcare, Inc.



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  223.25
+0.69 (0.31%)
AAPL  274.60
-0.01 (-0.00%)
AMD  202.16
-7.01 (-3.35%)
BAC  54.97
+0.16 (0.28%)
GOOG  299.27
-8.46 (-2.75%)
META  657.20
+0.05 (0.01%)
MSFT  475.76
-0.63 (-0.13%)
NVDA  172.36
-5.36 (-3.02%)
ORCL  177.65
-11.00 (-5.83%)
TSLA  480.20
-9.68 (-1.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.